These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

855 related items for PubMed ID: 15640958

  • 21. Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors--International Breast Cancer Study Group.
    Viale G, Regan MM, Maiorano E, Mastropasqua MG, Golouh R, Perin T, Brown RW, Kovács A, Pillay K, Ohlschlegel C, Braye S, Grigolato P, Rusca T, Gelber RD, Castiglione-Gertsch M, Price KN, Goldhirsch A, Gusterson BA, Coates AS.
    J Clin Oncol; 2008 Mar 20; 26(9):1404-10. PubMed ID: 18349391
    [Abstract] [Full Text] [Related]

  • 22. Short-term outcome of primary operated early breast cancer by hormone and HER-2 receptors.
    Brouckaert O, Pintens S, Van Belle V, Van Huffel S, Camerlynck E, Amant F, Leunen K, Smeets A, Berteloot P, Van Limbergen E, Decock J, Hendrickx W, Weltens C, Van den Bogaert W, Vanden Bempt I, Drijkoningen M, Paridaens R, Wildiers H, Vergote I, Christiaens MR, Neven P.
    Breast Cancer Res Treat; 2009 May 20; 115(2):349-58. PubMed ID: 18629635
    [Abstract] [Full Text] [Related]

  • 23. Prediction of response to neoadjuvant chemoendocrine therapy in primary breast carcinomas.
    Makris A, Powles TJ, Dowsett M, Osborne CK, Trott PA, Fernando IN, Ashley SE, Ormerod MG, Titley JC, Gregory RK, Allred DC.
    Clin Cancer Res; 1997 Apr 20; 3(4):593-600. PubMed ID: 9815725
    [Abstract] [Full Text] [Related]

  • 24. The role of carcinoembriogenic antigen in predicting response and survival to neoadjuvant chemoradiotherapy for distal rectal cancer.
    Perez RO, São Julião GP, Habr-Gama A, Kiss D, Proscurshim I, Campos FG, Gama-Rodrigues JJ, Cecconello I.
    Dis Colon Rectum; 2009 Jun 20; 52(6):1137-43. PubMed ID: 19581858
    [Abstract] [Full Text] [Related]

  • 25. Expression of epidermal growth factor receptor in breast cancer, from early stages to advanced disease.
    Nesković-Konstantinović Z, Nikolić-Vukosavljević D, Branković-Magić M, Kanjer K, Gavrilović D, Mitrović L, Borojević N, Vukotić D, Spuzić I.
    J Exp Clin Cancer Res; 1999 Sep 20; 18(3):347-55. PubMed ID: 10606181
    [Abstract] [Full Text] [Related]

  • 26. Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group.
    Kyndi M, Sørensen FB, Knudsen H, Overgaard M, Nielsen HM, Overgaard J, Danish Breast Cancer Cooperative Group.
    J Clin Oncol; 2008 Mar 20; 26(9):1419-26. PubMed ID: 18285604
    [Abstract] [Full Text] [Related]

  • 27. Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance.
    Arpino G, Weiss H, Lee AV, Schiff R, De Placido S, Osborne CK, Elledge RM.
    J Natl Cancer Inst; 2005 Sep 07; 97(17):1254-61. PubMed ID: 16145046
    [Abstract] [Full Text] [Related]

  • 28. Serum CEA as a predictor for the response to preoperative chemoradiation in rectal cancer.
    Park YA, Sohn SK, Seong J, Baik SH, Lee KY, Kim NK, Cho CW.
    J Surg Oncol; 2006 Feb 01; 93(2):145-50. PubMed ID: 16425302
    [Abstract] [Full Text] [Related]

  • 29. Molecular class as a predictor of locoregional and distant recurrence in the neoadjuvant setting for breast cancer.
    Vargo JA, Beriwal S, Ahrendt GM, Soran A, Johnson RR, McGuire K, Bhargava R.
    Oncology; 2011 Feb 01; 80(5-6):341-9. PubMed ID: 21791944
    [Abstract] [Full Text] [Related]

  • 30. Neoadjuvant chemotherapy in ER+ HER2- breast cancer: response prediction based on immunohistochemical and molecular characteristics.
    Lips EH, Mulder L, de Ronde JJ, Mandjes IA, Vincent A, Vrancken Peeters MT, Nederlof PM, Wesseling J, Rodenhuis S.
    Breast Cancer Res Treat; 2012 Feb 01; 131(3):827-36. PubMed ID: 21472434
    [Abstract] [Full Text] [Related]

  • 31. [The role of tumor receptor status in choosing adjuvant therapy for breast cancer patients of reproductive age].
    Samgina AA, Letiagin VP, Kuz'mina ZV.
    Vopr Onkol; 1992 Feb 01; 38(7):780-7. PubMed ID: 1300782
    [Abstract] [Full Text] [Related]

  • 32. Evaluation of Ki-67 proliferation and apoptotic index before, during and after neoadjuvant chemotherapy for primary breast cancer.
    Burcombe R, Wilson GD, Dowsett M, Khan I, Richman PI, Daley F, Detre S, Makris A.
    Breast Cancer Res; 2006 Feb 01; 8(3):R31. PubMed ID: 16790076
    [Abstract] [Full Text] [Related]

  • 33. An ER activity profile including ER, PR, Bcl-2 and IGF-IR may have potential as selection criterion for letrozole or tamoxifen treatment of patients with advanced breast cancer.
    Henriksen KL, Rasmussen BB, Lykkesfeldt AE, Møller S, Ejlertsen B, Mouridsen HT.
    Acta Oncol; 2009 Feb 01; 48(4):522-31. PubMed ID: 19173092
    [Abstract] [Full Text] [Related]

  • 34. [The effect of the microenvironment of head and neck cancers on tumor progression].
    Lukits J.
    Magy Onkol; 2009 Mar 01; 53(1):51-9. PubMed ID: 19318327
    [Abstract] [Full Text] [Related]

  • 35. Local recurrence after mastectomy for breast cancer: analysis of clinicopathological, biological and prognostic characteristics.
    Carreño G, Del Casar JM, Corte MD, González LO, Bongera M, Merino AM, Juan G, Obregón R, Martínez E, Vizoso FJ.
    Breast Cancer Res Treat; 2007 Mar 01; 102(1):61-73. PubMed ID: 16850244
    [Abstract] [Full Text] [Related]

  • 36. Immunophenotype of ovarian cancer as predictor of clinical outcome: evaluation at primary surgery and second-look procedure.
    Goff BA, Ries JA, Els LP, Coltrera MD, Gown AM.
    Gynecol Oncol; 1998 Sep 01; 70(3):378-85. PubMed ID: 9790791
    [Abstract] [Full Text] [Related]

  • 37. Evaluation of changes in biologic markers ER, PR, HER 2 and Ki-67 index in breast cancer with administration of neoadjuvant dose dense doxorubicin, cyclophosphamide followed by paclitaxel chemotherapy.
    Dede DS, Gumuskaya B, Guler G, Onat D, Altundag K, Ozisik Y.
    J BUON; 2013 Sep 01; 18(2):366-71. PubMed ID: 23818347
    [Abstract] [Full Text] [Related]

  • 38. Clinical value of TPS, CEA and CA 15-3 in breast cancer patients.
    Blijlevens NM, Oosterhuis WP, Oosten HR, Mulder NH.
    Anticancer Res; 1995 Sep 01; 15(6B):2711-6. PubMed ID: 8669851
    [Abstract] [Full Text] [Related]

  • 39. [Demonstration of the effect of estrogen and progesterone receptors on survival in breast cancer without cytostatic and hormonal treatment in a small set of patients].
    Hochmann J.
    Klin Onkol; 2010 Sep 01; 23(1):25-33. PubMed ID: 20192071
    [Abstract] [Full Text] [Related]

  • 40. Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer.
    Baselga J, Semiglazov V, van Dam P, Manikhas A, Bellet M, Mayordomo J, Campone M, Kubista E, Greil R, Bianchi G, Steinseifer J, Molloy B, Tokaji E, Gardner H, Phillips P, Stumm M, Lane HA, Dixon JM, Jonat W, Rugo HS.
    J Clin Oncol; 2009 Jun 01; 27(16):2630-7. PubMed ID: 19380449
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 43.